Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients

被引：40

作者：

Piscitelli, SC

Figg, WD

Hahn, B

Kelly, G

Thomas, S

Walker, RE

机构：

[1] NCI,CLIN PHARMACOKINET SECT,NIH,BETHESDA,MD 20892

[2] NIAID,IMMUNOREGULAT LAB,NIH,BETHESDA,MD 20892

[3] CELGENE CORP,WARREN,NJ

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1997年 / 41卷 / 12期

关键词：

D O I：

10.1128/AAC.41.12.2797

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The pharmacokinetics of thalidomide in nine human immunodeficiency virus-infected patients were studied. Single doses of thalidomide were well absorbed, with mean peak concentrations (+/- standard deviations) of 1.17 +/- 0.21 and 3.47 +/- 1.14 mu g/ml in the 100- and 300-mg dosing groups, respectively, and the mean elimination half-life was approximately 6 h. Adverse effects were mild, with drowsiness being reported for seven of nine patients.

引用

页码：2797 / 2799

页数：3

共 21 条

[1]

Ball SC, 1997, AM J GASTROENTEROL, V92, P169

[2]

CHEN TL, 1989, DRUG METAB DISPOS, V17, P402

[3]

DARGENIO DZ, 1990, ADAPT 2 USERS GUIDE

[4]

DOHERTY GM, 1991, SURGERY, V110, P192

[5]

Gibaldi M. P., 1982, PHARMACOKINETICS

[6] THALIDOMIDE TREATMENT FOR CHRONIC GRAFT-VERSUS-HOST DISEASE [J].

HENEY, D ;

NORFOLK, DR ;

WHEELDON, J ;

BAILEY, CC ;

LEWIS, IJ ;

BARNARD, DL .

BRITISH JOURNAL OF HAEMATOLOGY, 1991, 78 (01) :23-27

[7]

HUUPPONEN R, 1995, CLIN CHEM, V41, P1199

[8] Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection [J].

Jacobson, JM ;

Greenspan, JS ;

Spritzler, J ;

Ketter, N ;

Fahey, JL ;

Jackson, JB ;

Fox, L ;

Chernoff, M ;

Wu, AW ;

MacPhail, LA ;

Vasquez, GJ ;

Wohl, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (21) :1487-1493

[9]

JUSKO WJ, 1992, APPL PHARM PRINCIPLE

[10] INDICATIONS FOR THALIDOMIDE THERAPY FOR LEPROSY [J].

KLUKEN, N ;

WENTE, W .

INTERNATIONAL JOURNAL OF DERMATOLOGY, 1974, 13 (01) :20-25

← 1 2 3 →